KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Liabilities: 2017-2025

Historic Total Liabilities for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $167.7 million.

  • Aquestive Therapeutics' Total Liabilities rose 7.91% to $167.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $167.7 million, marking a year-over-year increase of 7.91%. This contributed to the annual value of $161.6 million for FY2024, which is 1.42% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Total Liabilities of $167.7 million as of Q3 2025, which was up 0.83% from $166.3 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Total Liabilities ranged from a high of $175.6 million in Q4 2022 and a low of $113.7 million during Q1 2021.
  • For the 3-year period, Aquestive Therapeutics' Total Liabilities averaged around $163.0 million, with its median value being $163.6 million (2023).
  • In the last 5 years, Aquestive Therapeutics' Total Liabilities surged by 44.51% in 2021 and then declined by 6.67% in 2023.
  • Aquestive Therapeutics' Total Liabilities (Quarterly) stood at $144.1 million in 2021, then climbed by 21.85% to $175.6 million in 2022, then declined by 6.67% to $163.9 million in 2023, then dropped by 1.42% to $161.6 million in 2024, then increased by 7.91% to $167.7 million in 2025.
  • Its Total Liabilities stands at $167.7 million for Q3 2025, versus $166.3 million for Q2 2025 and $163.2 million for Q1 2025.